Drug Profile
APN 1125
Alternative Names: APN1125Latest Information Update: 18 Dec 2019
Price :
$50
*
At a glance
- Originator CoMentis
- Developer Alpharmagen; CoMentis
- Class Antipsychotics
- Mechanism of Action Alpha7 nicotinic acetylcholine receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Schizophrenia
Most Recent Events
- 18 Dec 2019 No development reported - Phase-I/II for Schizophrenia in USA (PO)
- 01 Apr 2016 Phase-I/II clinical trials in Schizophrenia in USA (PO) (NCT02724917)
- 30 Mar 2016 CoMentis and Alpharmagen plan a phase Ib/IIa trial for Schizophrenia (Treatment-experienced) in USA (PO) (NCT02724917)